Research Article

Evaluation of Computed Tomography, Clinical and Laboratory Findings of COVID-19 in Cancer Patients

Volume: 22 Number: Special Issue November 30, 2020
TR EN

Evaluation of Computed Tomography, Clinical and Laboratory Findings of COVID-19 in Cancer Patients

Abstract

Aim: The aim of this study was to evaluate the computed tomography (CT), clinical and laboratory findings of coronavirus disease 2019 (COVID-19) in cancer patients and to compare the findings between polymerase chain reaction (PCR) positive and negative patients. Material and Methods: Twenty-three cancer patients with positive PCR tests and 22 diagnosed as COVID-19 with clinical and radiological findings were included in the study. CT images of the patients were evaluated simultaneously by two radiologists. Presence of comorbid diseases, symptoms and laboratory values were evaluated. Results: The most common CT involvement pattern was peripheral with 88.9% (n=40). Bilateral lung involvement rate was 57.8% (n=26). The most common finding was ground glass opacities (n=38, 84.5%). 35.6% (n=16) of these were accompanied by consolidation. Multifocal involvement was present in 62.2% (n=28) of the cases. The most frequently involved lobes were lower lobes. Other relatively common findings were septal thickening, subpleural streaking, and air bronchogram. The median neutrophil, lymphocyte, D-dimer, procalcitonin, C-reactive protein and lactate dehydrogenase values of the patients were 2000 mm3, 1200 mm3, 1990 ng/mL, 30.7 mcg/L 15.8 mg/dl, 161 IU/L, respectively. Conclusion: Multifocal and bilateral involvement, and ground glass opacities were the most common findings. However, higher rates of septal thickening, which is generally less common, suggest that the findings may be more severe in cancer patients. Most of the inflammatory markers were higher in PCR negative cases. Studies with more patients in multiple centers will provide better comparison of the findings in cancer patients with the general population.

Keywords

References

  1. Ufuk F, Savas R. Chest CT features of the novel coronavirus disease (COVID-19). Turk J Med Sci. 2020;50(4):664-78.
  2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020:382(8):727-33.
  3. Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B. COVID-19-associated acute hemorrhagic necrotizing encephalopathy: Imaging features. Radiology. 2020:296(2):E119-20.
  4. Yang K, Sheng Y, Huang C, Jin Y, Xiong N, Jiang K, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020;21(7):904-13.
  5. Meng Y, Lu W, Guo E, Liu J, Yang B, Wu P, et al. Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: a propensity score-matched analysis. J Hematol Oncol. 2020;13(1):75.
  6. Robilotti EV, Babady NE, Mead PA, Rolling T, Perez-Johnston R, Bernardes M, et al. Determinants of COVID-19 disease severity in patients with cancer. Nat Med. 2020;26(8):1218-23.
  7. Assaad S, Avrillon V, Fournier ML, Mastroianni B, Russias B, Swalduz A, et al. High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-CoV-2 on RT-PCR. Eur J Cancer. 2020;135:251-9.
  8. Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med. 2020;58(7):1131-4.

Details

Primary Language

English

Subjects

Clinical Sciences

Journal Section

Research Article

Publication Date

November 30, 2020

Submission Date

September 15, 2020

Acceptance Date

November 11, 2020

Published in Issue

Year 2020 Volume: 22 Number: Special Issue

APA
Köşeci, T., Kaya, Ö., Dilek, O., Alişan, İ., Haksöyler, V., Bozkurt Duman, B., & Çil, T. (2020). Evaluation of Computed Tomography, Clinical and Laboratory Findings of COVID-19 in Cancer Patients. Duzce Medical Journal, 22(Special Issue), 56-60. https://doi.org/10.18678/dtfd.795333
AMA
1.Köşeci T, Kaya Ö, Dilek O, et al. Evaluation of Computed Tomography, Clinical and Laboratory Findings of COVID-19 in Cancer Patients. Duzce Med J. 2020;22(Special Issue):56-60. doi:10.18678/dtfd.795333
Chicago
Köşeci, Tolga, Ömer Kaya, Okan Dilek, et al. 2020. “Evaluation of Computed Tomography, Clinical and Laboratory Findings of COVID-19 in Cancer Patients”. Duzce Medical Journal 22 (Special Issue): 56-60. https://doi.org/10.18678/dtfd.795333.
EndNote
Köşeci T, Kaya Ö, Dilek O, Alişan İ, Haksöyler V, Bozkurt Duman B, Çil T (November 1, 2020) Evaluation of Computed Tomography, Clinical and Laboratory Findings of COVID-19 in Cancer Patients. Duzce Medical Journal 22 Special Issue 56–60.
IEEE
[1]T. Köşeci et al., “Evaluation of Computed Tomography, Clinical and Laboratory Findings of COVID-19 in Cancer Patients”, Duzce Med J, vol. 22, no. Special Issue, pp. 56–60, Nov. 2020, doi: 10.18678/dtfd.795333.
ISNAD
Köşeci, Tolga - Kaya, Ömer - Dilek, Okan - Alişan, İrfan - Haksöyler, Veysel - Bozkurt Duman, Berna - Çil, Timuçin. “Evaluation of Computed Tomography, Clinical and Laboratory Findings of COVID-19 in Cancer Patients”. Duzce Medical Journal 22/Special Issue (November 1, 2020): 56-60. https://doi.org/10.18678/dtfd.795333.
JAMA
1.Köşeci T, Kaya Ö, Dilek O, Alişan İ, Haksöyler V, Bozkurt Duman B, Çil T. Evaluation of Computed Tomography, Clinical and Laboratory Findings of COVID-19 in Cancer Patients. Duzce Med J. 2020;22:56–60.
MLA
Köşeci, Tolga, et al. “Evaluation of Computed Tomography, Clinical and Laboratory Findings of COVID-19 in Cancer Patients”. Duzce Medical Journal, vol. 22, no. Special Issue, Nov. 2020, pp. 56-60, doi:10.18678/dtfd.795333.
Vancouver
1.Tolga Köşeci, Ömer Kaya, Okan Dilek, İrfan Alişan, Veysel Haksöyler, Berna Bozkurt Duman, Timuçin Çil. Evaluation of Computed Tomography, Clinical and Laboratory Findings of COVID-19 in Cancer Patients. Duzce Med J. 2020 Nov. 1;22(Special Issue):56-60. doi:10.18678/dtfd.795333